<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102559">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01967160</url>
  </required_header>
  <id_info>
    <org_study_id>20101363</org_study_id>
    <nct_id>NCT01967160</nct_id>
  </id_info>
  <brief_title>Osteonecrosis of the Jaw (ONJ) and Infection Among Nordic Cancer Patients Treated With XGEVA™ or Zoledronic Acid</brief_title>
  <official_title>A Non-interventional Pharmacovigilance Study of Osteonecrosis of the Jaw and Infection Leading to Hospitalization Among Patients With Cancer Treated With XGEVA™ or Zoledronic Acid in Sweden, Denmark, and Norway</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <authority>Sweden: The National Board of Health and Welfare</authority>
    <authority>Norway: Regional Ethics Commitee</authority>
    <authority>Denmark: National Board of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      A non-interventional study to assess incident rates of Osteonecrosis of the Jaw and
      Infections leading to hospitalization in Cancer patients treated with XGEVA™ in Sweden,
      Denmark and Norway.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>1. Incidence proportions of medically confirmed osteonecrosis of the jaw (ONJ) in XGEVA and zoledronic acid inception cohorts</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>2. Incidence proportions of infections leading to hospitalization in XGEVA and zoledronic acid inception cohorts</measure>
    <time_frame>3 years</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>1. Incidence proportions of medically confirmed ONJ in the cohort switching from IV bisphosphonate to XGEVA</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2. Incidence proportions of medically confirmed ONJ in the cohort switching from IV bisphosphonate to XGEVA stratified by number of prior cancer-related bisphosphonate treatments</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3. Number of bisphosphonate treatments prior to initiation of XGEVA treatment for patients in the cohort switching from IV bisphosphonate to XGEVA</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">3600</enrollment>
  <condition>ONJ</condition>
  <condition>Infection</condition>
  <arm_group>
    <arm_group_label>XGEVA inception cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Zoledronic acid inception cohort</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>XGEVA-switch cohort</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Cancer patients treated with antiresorptive therapies
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years old

          -  diagnosed with cancer

          -  subsequent to cancer diagnosis, initiating cancer-related antiresorptive treatment
             during the treatment cohort identification period with XGEVA or zoledronic acid or
             switching to XGEVA from cancer-related treatment with oral or IV bisphosphonates of
             less than 2 years duration (≤ 24 IV infusions or ≤ 24 monthly oral prescriptions)

        Exclusion Criteria:

          -  history of radiation treatment for head and neck cancer before a subject's potential
             index date

          -  hypercalcemia of malignancy as the indication for treatment with an anti-resorptive
             agent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 25, 2013</lastchanged_date>
  <firstreceived_date>October 18, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Osteonecrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Zoledronic acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
